| Bioactivity | Bevifimod (PRTX-100) is a highly purified form of Staphylococcal protein A (SpA). Bevifimod can be used for idiopathic thrombocytopenic purpura (ITP) research[1][2]. |
| Invitro | Bevifimod（PRTX-100；250、25 和 2.5 ng/mL；48 小时）抑制外周血单核细胞 (PBMC) 中人单核细胞对 W632 调理血小板的吞噬作用[1]。 |
| In Vivo | Bevifimod (PRTX-100; 2.5-250 μg/kg; i.v.; once every two weeks; for 4 weeks) increases platelet counts to within normal levels within 1-2 weeks and none of the mice died[2]. Animal Model: |
| Name | Bevifimod |
| CAS | 2223113-32-2 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. ChrisYatkoBS, et al. PRTX-100 Inhibits Platelet Phagocytosis In Vitro. Blood (2006) 108 (11): 1081. [2]. John W. Semple, et al. Successful Treatment of Thrombocytopenia with Staphylococcal Protein A (PRTX-100) in a Murine Model of Immune Thrombocytopenia (ITP). Blood (2015) 126 (23): 1045. |